COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
申请人:Yuhan Corporation
公开号:US20160102076A1
公开(公告)日:2016-04-14
The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.
[EN] THIAZOLIDINONES, OXAZOLIDINONES, AND PYRROLIDINONES FOR HBV<br/>[FR] THIAZOLIDINONES, OXAZOLIDINONES ET PYRROLIDINONES POUR LE VHB
申请人:VALEANT RES & DEV
公开号:WO2007014023A1
公开(公告)日:2007-02-01
[EN] The present invention relates to certain single-enantiomer pyrrazol-4-yl derivatives of thiazolidinones, oxazolidinones, and pyrrolidinones which are useful in the treatment of Hepatitis B virus. [FR] La présente invention se rapporte à certains pyrrazol-4-yls à énantiomère unique dérivés de thiazolidinones, d'oxazolidinones et de pyrrolidinones qui sont utiles dans le traitement du virus de l'hépatite B.
[EN] COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS À MODULER LES ACTIVITÉS KINASE DE L'EGFR MUTANT
申请人:YUHAN CORP
公开号:WO2016060443A2
公开(公告)日:2016-04-21
The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.